Article info

Download PDFPDF

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma
Free

Authors

  1. a daniel.geynisman{at}uchospitals.edu
  2. b yzha1{at}bsd.uchicago.edu
  3. c rangeshk{at}uchicago.edu
  4. d Mebea.Aklilu{at}advocatehealth.com
  5. e dcatenac{at}medicine.bsd.uchicago.edu
  6. f bpolite{at}medicine.bsd.uchicago.edu
  7. g Cara.Rosenbaum{at}uchospitals.edu
  8. h Azadeh.Namakydoust{at}uchospitals.edu
  9. i tkarrison{at}health.bsd.uchicago.edu
  10. j tgajewsk{at}medicine.bsd.uchicago.edu
  11. k hkindler{at}medicine.bsd.uchicago.edu
View Full Text

Citation

Geynisman DM, Zha Y, Kunnavakkam R, et al
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

Publication history

  • Received February 26, 2013
  • Accepted April 15, 2013
  • First published June 27, 2013.
Online issue publication 
June 27, 2013

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.